Block copolymer, liquid composite thereof, nucleic acid preparation, preparation methods therefor, and use thereof
Provided are a polycaprolactone-polyphosphate block copolymer, a liquid composite formed by the block copolymer, a nucleic acid preparation, preparation methods for the copolymer and the liquid composite, and the use of the copolymer and the liquid composite in a nucleic acid medicine delivery system. The block copolymer prepared using the present invention has good biocompatibility, low cytotoxicity, and good biodegradability. The micelles provided in the present invention self-assemble into nano-particles in an aqueous solution, and have good stability, biocompatibility, and biodegradability, and low cytotoxicity. The preparation method is simple, has high repeatability, as a vector can protect small nucleic acids such as siRNA from biodegradation, can combine with the scale effect of nano-particles, and can be used for treating different diseases. Additionally, bonding targeting groups enable specificity recognition of different cancer cells.
1. A block copolymer, wherein the block copolymer is consisting of Block A and Block B, Block A is a polycaprolactone block, Block B is a polyphosphate block having the structural unit represented by Formula I,
wherein, R 1 is an optionally substituted C2-C10 alkylene and X is a halogen;
in the block copolymer, the weight ratio between Block A and Block B is 1:0.1-5.3.
2. The block copolymer according to claim 1 , wherein the polycaprolactone block has the structure represented by Formula II, and the block copolymer is an A-B diblock copolymer,
wherein, R 2 is an optionally substituted C1-C10 alkyl and m is an integer greater than 1; preferably, the average molecular weight of the polycaprolactone block is 500-40000.
3. The block copolymer according to claim 1 , wherein the average molecular weight of the polyphosphate block is 500-10000.
4. A liquid composition, wherein the liquid composition contains water and micellar nano-particles, the micellar nano-particles are formed by a second block copolymer or by a first block copolymer and a second block copolymer together, wherein the first block copolymer is a polycaprolactone-polyethylene glycol block copolymer, the second block copolymer is the block copolymer according to claim 1 , and the molar ratio between the first block copolymer and the second block copolymer is 0-100:1.
5. The liquid composition according to claim 4 , wherein the particle diameter of the micellar nano-particles is 10-250 nm and the Zeta potential of the micellar nano-particles is 10-100 mV.
6. The liquid composition according to claim 4 , wherein the first block copolymer is a polycaprolactone-polyethylene glycol diblock copolymer; wherein in the first block copolymer, the average molecular weight of the polycaprolactone block is 200-25000, and the average molecular weight of the polyethylene glycol block is 200-10000.
7. The liquid composition according to claim 6 , wherein at least part of the polyethylene glycol block is modified by a targeting substance, and the targeting substance is at least one of a folic acid, a saccharide, an oligopeptide, a monoclonal antibody and an aptamer.
8. The liquid composition according to claim 7 , wherein the saccharide is acetyl galactose.
9. The liquid composition according to claim 4 , wherein, in the liquid composition, the concentration of the first block copolymer is 0−5×10 −3 M, and the concentration of the second block copolymer is 1×10 −5 −5×10 −3 M.
10. A method for preparing a liquid composition, wherein the method includes: contacting a second block copolymer with an organic solvent, or contacting a first block copolymer and a second block copolymer with an organic solvent, to obtain a first solution; and contacting the first solution with water under stirring, wherein the first block copolymer is a polycaprolactone-polyethylene glycol block copolymer, the second block copolymer is the block copolymer according to claim 1 , the molar ratio between the first block copolymer and the second block copolymer is 0-100:1, and the organic solvent is miscible with water.
11. The method according to claim 10 , wherein the organic solvent is at least one of dimethyl sulfoxide, acetonitrile and a C1-C6 alcohol.
12. The method according to claim 10 , wherein the method further includes: dialyzing the solution obtained by contacting the first solution with water to remove the organic solvent therein.
13. A nucleic acid preparation, wherein the preparation comprises a nucleic acid as an active ingredient and a vector, wherein the vector is micellar nano-particles formed by a second block copolymer or by a first block copolymer and a second block copolymer together, the first block copolymer is a polycaprolactone-polyethylene glycol block copolymer, the second block copolymer is a block copolymer according to claim 1 , the molar ratio between the first block copolymer and the second block copolymer is 0-100:1, and the molar ratio between the second block copolymer and the nucleic acid is 0.1-1000:1.
14. The nucleic acid preparation according to claim 13 , wherein the molar ratio between nitrogen atoms in the vector and phosphorus atoms in the main chain of the nucleic acid is 1-100:1.
15. The nucleic acid preparation according to claim 13 , wherein the particle diameter of the micellar nano-particles is 10-250 nm and the Zeta potential of the micellar nano-particles is 10-100 mV.
16. The nucleic acid preparation according to claim 13 , wherein the first block copolymer is a polycaprolactone-polyethylene glycol diblock copolymer; wherein the average molecular weight of the polycaprolactone block is 200-25000 and the average molecular weight of the polyethylene glycol block is 200-10000.
17. The nucleic acid preparation according to claim 16 , wherein at least part of the polyethylene glycol block is modified by a targeting substance, and the targeting substance is at least one of a folic acid, a saccharide, an oligopeptide, a monoclonal antibody and an aptamer.
18. The nucleic acid preparation according to claim 17 , wherein the saccharide is acetyl galactose.
19. The nucleic acid preparation according to claim 13 , wherein the nucleic acid is at least one of a siRNA, a microRNA, a shRNA, an antisense RNA and an aptamer.
20. A method of treating cancer in a human patient in need thereof, comprising administering a therapeutically effective amount of the nucleic acid preparation according to claim 13 , to a cancerous tumor, in the human patient; wherein the cancer is selected from the group consisting of: lung cancer, prostate cancer, and liver cancer.
21. A method for preparing a block copolymer, wherein the method includes the following steps,
(1) under conditions of ring-opening polymerization and in the presence of a ring-opening polymerization catalyst, contacting a polycaprolactone and the compound having the structural unit represented by Formula III with a first organic solvent, to obtain a first product,
wherein, R 3 is an optionally substituted C2-C10 alkylene, R 4 is a protecting group of amino, and the weight ratio between the polycaprolactone and the compound having the structural unit represented by Formula III is 1:1-30;
(2) under an acidic condition, removing the protecting group of amino R 4 from the first product to obtain the block copolymer.
22. The method according to claim 21 , wherein the polycaprolactone has the structural unit represented by Formula IV,
wherein, R 5 is an optionally substituted C1-C10 alkyl and m is an integer greater than 1; preferably, the average molecular weight of the polycaprolactone is 500-40000.
23. The method according to claim 21 , wherein the conditions of ring-opening polymerization include temperature of 20-50° C. and duration of 1-10 hours; the ring-opening polymerization catalyst is stannous iso-caprylate; and the first organic solvent is at least one of tetrahydrofuran, dimethyl sulfoxide and toluene.
24. The method according to claim 21 , wherein the compound having the structural unit represented by Formula III is synthesized by: contacting the compound having the structural unit represented by Formula V with 2-chloro-2-oxo-1,3,2-dioxaphospholane under the condition of alcoholysis of acyl chloride,
wherein, R 6 is an optionally substituted C2-C10 alkylene.